Trump Suggests Federal Approval for "Natural" 7-OH, Contradicting FDA Push to Schedule It

Why it matters

President Trump's statement signals a potential federal policy reversal that could upend ongoing FDA efforts to schedule 7-OH as a controlled substance, creating regulatory uncertainty for states that have already enacted bans.

The big picture

7-hydroxymitragynine (7-OH) is a potent opioid alkaloid found naturally in trace amounts in kratom but increasingly sold in concentrated, semi-synthetic forms at gas stations and convenience stores. The FDA warned in July 2025 that it would move to schedule 7-OH, and multiple states including Kansas, Kentucky, and Utah have already enacted bans. Trump's comments introduce a new dimension: the possibility of a federal approval pathway for what he described as "natural" 7-OH, a term experts say has no clear scientific definition.

Key findings

• President Trump stated on May 11, 2026: "We're looking very seriously at natural 7-OH and getting that approved"
• The statement directly contradicts the FDA's July 2025 announcement that it would move to restrict 7-OH products threatening American consumers
• It is not clear what Trump meant by "natural 7-OH" — the compound occurs in small amounts in kratom leaves but is commonly sold in highly concentrated semi-synthetic forms
• While kratom is considered less dangerous than fentanyl or prescription opioids, kratom can still cause addiction and overdose
• At least a dozen states have passed or are advancing bans specifically targeting 7-OH; a federal approval pivot could nullify those efforts

What they say

"We're looking very seriously at natural 7-OH and getting that approved," President Trump said on May 11, 2026, according to STAT News reporting.

Bottom line

President Trump's public suggestion that "natural" 7-OH could be federally approved marks a major shift in federal posture and puts the FDA's pending restriction efforts in direct conflict with White House priorities.